Drug Trial Radar · NCT04776018
A Study Of TAK-981 Given With Monoclonal Antibodies (mAbs) In Adults With Relapsed or Refractory Multiple Myeloma (RRMM)
Last checked: Nov 19, 2026Latest source record: Oct 2, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
27
Actual
Start
Apr 20, 2021
Primary completion
Aug 2, 2023
Study completion Nov 9, 2023
Sponsor
- Lead sponsor
- TakedaTakeda (TAK)
- Sponsor type
- Industry
- First posted
- Mar 1, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
TAK-981 is being tested in combination with anti-CD38 monoclonal antibodies (mAbs) to treat participants who have relapsed or refractory multiple myeloma (RRMM). The main aims of the study are to evaluate the safety and efficacy of TAK-981 in combination with anti-CD38 (mAbs) and to determine the recommended Phase 2 dose (RP2D). Participants will be on this combination treatment for 28-day cycles. They will continue with this treatment until disease progression or unacceptable toxicity.
Conditions
- Relapsed and/or Refractory Multiple Myeloma (RRMM)
Interventions
TAK-981Drug
TAK-981 IV infusion.
MezagitamabDrug
Mezagitamab SC injection.
Daratumumab and Hyaluronidase-fihjDrug
Daratumumab and Hyaluronidase-fihj SC injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1b, Part 1: Number of Participants With One or More Treatment Emergent Adverse Events (TEAEs)Time frame: From the first dose of study drug through 30 days after the last dose of study drug (up to 13 months)
- Phase 1b, Part 1: Number of Participants With Grade 3 or Higher TEAEsTime frame: From the first dose of study drug through 30 days after the last dose of study drug (up to 13 months)
- Phase 1b, Part 1: Number of Participants With Dose Limiting Toxicities (DLTs) Based on NCI CTCAE Version 5.0Time frame: Cycle 1 (Cycle length = 28 Days)
- Phase 2: Overall Response Rate (ORR)Time frame: From date of treatment start to until date of first PD or death (whichever occurred first), up to 24 months
Locations
13 sites in 2 countries. Site status is shown where the registry gives one.
Mayo Clinic Arizona - PPDS
Scottsdale, Arizona
Mayo Clinic Jacksonville - PPDS
Jacksonville, Florida
Winship Cancer Institute, Emory University
Atlanta, Georgia
Indiana University
Indianapolis, Indiana
American Oncology Partners of Maryland, PA
Bethesda, Maryland
Mayo Clinic - Cancer Center - Rochester - PPDS
Rochester, Minnesota
Oncology Hematology West (Omaha) - USOR
Omaha, Nebraska
Weill Cornell Medical Center
New York, New York
TriHealth Cancer Institute
Cincinnati, Ohio
Baylor Sammons Cancer Center
Dallas, Texas
Northeast Texas Cancer and Research Institute
Tyler, Texas
Medical College of Wisconsin Cancer Center
Milwaukee, Wisconsin
Hopital Maisonneuve-Rosemont
Montreal, Quebec, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.